The Diabetes Center Berne today announced the launch of an initiative to develop technology to address the treatment of diabetes. DCB is seeking innovators, co-creators, scientists and members of the diabetes community to join the company’s innovation challenge and join its community of diabetes technology developers. The center requested anyone ranging from members of start-ups, […]
Diabetes
Researchers reverse diabetes in mice using nanoscale device
Scientists at Washington University (St. Louis) and Cornell University (Ithaca, N.Y.) successfully implanted insulin-secreting cells in mice with type 1 diabetes. The cells proved capable of reversing chemically-induced diabetes for up to 200 days after implantation, according to a recent article in Science Translational Medicine. To do so, they used a nanofiber-integrated cell encapsulation (NICE) device […]
Study shows CGMs better at controlling blood sugar in type 2 diabetes
Kaiser Permanente is touting a study demonstrating that using continuous glucose monitors offers better blood sugar control for patients with type 2 diabetes. The study found that patients with insulin-treated type 2 diabetes using continuous glucose monitors (CGMs) typically had better blood sugar control and fewer visits to the emergency room for hypoglycemia. The study […]
How Fractyl Health is ‘reversing’ type 2 diabetes to reduce or eliminate insulin injections
Fractyl Health CEO Harith Rajagopalan envisions a scenario in which those with type 2 diabetes don’t have to rely on insulin injections. Insulin has long been a staple of treatment for type 2 diabetes patients who need to manage their blood sugar levels, but Rajagopalan’s aim is to go beyond that temporary fix. Trained as […]
FDA issues draft clinical trial guidelines for neurostim, other devices to treat diabetes
The FDA today issued a draft guidance with recommendations for clinical trials for certain devices intended for treating diabetes. Included in the guidance are recommendations for feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with type 2 diabetes mellitus, independent of medication delivery. Among the […]
Once-a-week insulin dosing shows promise in studies
Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes. Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according […]
Famed marathoner uses Abbott glucose sensor for training
Kenyan long-distance runner Eliud Kipchoge is using a glucose sensor modeled after Abbott Laboratories’ FreeStyle Libre glucose monitor to optimize his training regimen. The sensor, known as the Libre Sense Glucose Sport Biosensor, is the first device intended to help athletes track blood sugar rather than people with diabetes. Kipchoge, who set a world record […]
Virta Health touts study of treatment preventing progression to Type 2 diabetes
Virta Health announced today that a study of its diabetes progression prevention treatment proved more effective than initially expected. Peer-reviewed research in Nutrients highlighted the fact that only 3% of trial participants progressed to Type 2 diabetes, while over half achieved prediabetes reversal during the first two years, according to a news release. Additionally, the […]
Semaglutide paired with behavioral therapy tripled weight loss in trial
The diabetes drug Ozempic (semaglutide) could potentially enhance weight loss in overweight and obese patients without diabetes, according to a study recently published in JAMA and The New England Journal of Medicine. In December, Novo Nordisk (NYSE:NVO) submitted a new drug application to the FDA for a 2.4-mg dose of subcutaneous semaglutide for chronic weight management. Get the full story […]
Dexcom Q4 earnings miss by a penny — but revenue up 23%
Dexcom (NSDQ:DXCM) reported mixed Q4 2020 results and reiterated a fiscal year 2021 revenue guidance that is slightly below Wall Street projections. The San Diego–based continuous glucose monitor company yesterday evening reported profits of $355.2 million, or $3.48 per share, on sales of $568.9 million for the three months ended Dec. 31, 2020, nearly quadrupling the […]
